ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC
Authors:
- 1 September 2021
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 39 (9) , 1178-1180
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Bristol-Myers Squibb
- EMD Serono
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals U.S.A.
- Eli Lilly and Company
- Merck KGaA
This publication has 9 references indexed in Scilit:
- Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyCancer Cell, 2021
- Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent PhenotypeJournal of Thoracic Oncology, 2020
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With AdvancedEGFR-Mutant Non–Small Cell Lung CancerJAMA Oncology, 2019
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialThe Lancet Oncology, 2019
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyThe Lancet Oncology, 2014
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialThe Lancet, 2011
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor ResistanceClinical Cancer Research, 2009